Q: What happens during a blood shortage?

Blood shortages are chronic in most LMICs and periodic in high-income countries (during natural disasters, pandemics like COVID-19, disasters). Consequences: elective surgeries cancelled; emergency trauma patients cannot receive needed transfusions; cancer patients miss chemotherapy-related support. Blood shortages are managed through: rationing protocols; deferral of elective procedures; patient blood management (reducing unnecessary transfusions); and emergency donor recruitment campaigns.

Q: What is patient blood management?

Patient blood management (PBM) is a patient-centred, evidence-based approach to optimise care by managing and preserving a patient's own blood — reducing or avoiding the need for allogeneic (donor) transfusion. Core components: treating pre-operative anaemia (iron supplementation, EPO); minimising intraoperative blood loss (surgical techniques, cell salvage); and evidence-based restrictive transfusion thresholds. PBM reduces transfusion use by 20-30% in hospitals that implement it.

Q: What is blood component therapy?

Whole blood is separated into components to allow more targeted and efficient use: red blood cells (for anaemia, oxygen delivery); platelets (for clotting — given to thrombocytopenic patients and those on chemotherapy); fresh frozen plasma (FFP — all coagulation factors — given for coagulopathy, massive haemorrhage); and cryoprecipitate (fibrinogen, factor VIII, von Willebrand factor — for specific deficiencies). Component therapy allows one donation to help 2-3 patients.

Q: What is haemovigilance?

Haemovigilance is the systematic monitoring of adverse events in the blood transfusion chain — from donor through processing, storage, distribution and patient transfusion. Adverse events include: transfusion reactions (haemolytic, febrile, allergic, TRALI, TACO); wrong blood events; TTIs; and near-miss incidents. National haemovigilance systems enable learning and safety improvement. WHO supports haemovigilance programme development in LMICs.

Q: How can I donate blood?

Eligibility criteria vary by country but generally include: age 18-65; weight above a threshold (typically >50 kg); no recent illness or surgery; no high-risk behaviour for TTIs in the past 12 months; and haemoglobin above the minimum threshold. Donation takes approximately 10-15 minutes; the full process including registration, screening and recovery takes approximately 45-60 minutes. Whole blood can be donated every 56-84 days. Contact your national blood service or the International Federation of Red Cross and Red Crescent Societies for local donation opportunities.

Question 1

How many blood donations are collected globally?

Accepted Answer

118.5 million blood donations are collected annually worldwide. However, 42% come from high-income countries that house only 16% of the global population. Low-income countries collect on average 4.6 donations per 1,000 population — compared to 31.5 in high-income countries. WHO recommends at least 10-20 donations per 1,000 population for a country to meet its basic needs.

Question 2

Why is voluntary non-remunerated donation safer?

Accepted Answer

Voluntary non-remunerated blood donors (VNRBD) — those motivated solely to save lives — are statistically safer donors than paid or family/replacement donors. Paid donors may conceal health risks to qualify; family/replacement donors are often recruited urgently without full assessment. Studies consistently show lower rates of transfusion-transmitted infections (HIV, HBV, HCV, syphilis) in blood from VNRBD. WHO targets 100% VNRBD as the gold standard for safe blood supply.

Question 3

How is blood screened for infections?

Accepted Answer

All donated blood should be screened for: HIV (antibody/antigen); hepatitis B surface antigen; hepatitis C antibody; and syphilis serology — as mandatory minimum requirements in WHO guidelines. High-income countries also use nucleic acid testing (NAT) which detects viral RNA/DNA within days of infection — eliminating the "window period" of early infection. Blood is also ABO and Rh typed, and crossmatched against the recipient before transfusion.

Question 4

What are transfusion-transmitted infections?

Accepted Answer

TTIs include infections transmitted via blood transfusion: HIV (risk approximately 1 in 1 million in screened blood in high-income countries; higher in LMICs without screening); HBV and HCV (similar risk profile); syphilis; Trypanosoma cruzi (Chagas disease in Latin America); malaria (relevant in endemic regions); cytomegalovirus (in immunocompromised recipients); and variant CJD (prion disease — led to exclusion of UK donors in Europe). Universal screening is the primary safeguard.

Question 5

Why do children need blood transfusions in low-income countries?

Accepted Answer

In low-income countries, up to 65% of blood transfusions go to children under 5 — primarily for severe malarial anaemia (haemoglobin <5 g/dL from red blood cell destruction by Plasmodium falciparum). Severe anaemia in children causes cardiac failure and death without urgent transfusion. This creates enormous pressure on blood supply systems that are often inadequately supplied, screened and stored.

Question 6

What happens during a blood shortage?

Accepted Answer

Blood shortages are chronic in most LMICs and periodic in high-income countries (during natural disasters, pandemics like COVID-19, disasters). Consequences: elective surgeries cancelled; emergency trauma patients cannot receive needed transfusions; cancer patients miss chemotherapy-related support. Blood shortages are managed through: rationing protocols; deferral of elective procedures; patient blood management (reducing unnecessary transfusions); and emergency donor recruitment campaigns.

Question 7

What is patient blood management?

Accepted Answer

Patient blood management (PBM) is a patient-centred, evidence-based approach to optimise care by managing and preserving a patient's own blood — reducing or avoiding the need for allogeneic (donor) transfusion. Core components: treating pre-operative anaemia (iron supplementation, EPO); minimising intraoperative blood loss (surgical techniques, cell salvage); and evidence-based restrictive transfusion thresholds. PBM reduces transfusion use by 20-30% in hospitals that implement it.

Question 8

What is blood component therapy?

Accepted Answer

Whole blood is separated into components to allow more targeted and efficient use: red blood cells (for anaemia, oxygen delivery); platelets (for clotting — given to thrombocytopenic patients and those on chemotherapy); fresh frozen plasma (FFP — all coagulation factors — given for coagulopathy, massive haemorrhage); and cryoprecipitate (fibrinogen, factor VIII, von Willebrand factor — for specific deficiencies). Component therapy allows one donation to help 2-3 patients.

Question 9

What is haemovigilance?

Accepted Answer

Haemovigilance is the systematic monitoring of adverse events in the blood transfusion chain — from donor through processing, storage, distribution and patient transfusion. Adverse events include: transfusion reactions (haemolytic, febrile, allergic, TRALI, TACO); wrong blood events; TTIs; and near-miss incidents. National haemovigilance systems enable learning and safety improvement. WHO supports haemovigilance programme development in LMICs.

Question 10

How can I donate blood?

Accepted Answer

Eligibility criteria vary by country but generally include: age 18-65; weight above a threshold (typically >50 kg); no recent illness or surgery; no high-risk behaviour for TTIs in the past 12 months; and haemoglobin above the minimum threshold. Donation takes approximately 10-15 minutes; the full process including registration, screening and recovery takes approximately 45-60 minutes. Whole blood can be donated every 56-84 days. Contact your national blood service or the International Federation of Red Cross and Red Crescent Societies for local donation opportunities.

Question 11

How does GMJ News cover blood safety?

Accepted Answer

GMJ News covers WHO global blood supply data, transfusion safety standards, Georgia's blood programme and voluntary donation campaigns. Blood safety is a direct concern for PHIG's healthcare quality work — Accreditation Canada standards include blood bank management and haemovigilance requirements for accredited Georgian hospitals.

GMJ News

Blood Safety

Key messages

Key statistics

Glossary of key terms

Latest GMJ coverage

Frequently asked questions 12 Q&A — structured for Google featured snippets and AI discovery

Knowledge hub: guidelines, conventions and reports

Organizations working in migration and health

Related health topics

Company